Physician profile
Michaele Snyder
NPI 1417520644
$2,353.44
in general payments reported to CMS, 2019-2025
13 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2022: $578 · 2023: $95.18 · 2024: $287 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.89 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $411.45 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $364.39 | 2022-2025 | Miebo, Xiidra |
| Biotissue Holdings INC. | $231.03 | 2022-2025 | |
| Dompe US, INC. | $194.10 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $165.55 | 2024-2025 | Tryptyr, Rocklatan |
| Apellis Pharmaceuticals, INC. | $116.42 | 2024 | Syfovre |
| Allergan, INC. | $111.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $108.72 | 2022 | |
| Coopervision INC. | $105.51 | 2021 | |
| Ocular Therapeutix, INC. | $66.12 | 2025 | Dextenza |
| Glaukos Corporation | $43.55 | 2021-2022 | |
| Thea Pharma INC. | $20.54 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaele Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.